New antiepileptic drugs in epileptology
New antiepileptic drugs in epileptology
复制标题
DOI：
10.1159/000026530
复制
发表时间：
1998-01-01
影响因子：
3.2
通讯作者：
Bauer, J
中科院分区：
文献类型：
--
作者：
Elger, CE;Bauer, J
新的抗癫痫药物已经开发并发布，用于治疗慢性局灶性和继发性全身性癫痫发作。这些药物（氨己烯酸、拉莫三嗪、加巴喷丁、非氨酯、噻加宾、托吡酯和奥卡西平）的抗惊厥疗效似乎并不上级传统抗惊厥药。这些新开发的药物的主要优点是可能的不良事件的不同谱（即这些药物通常不会诱导镇静）。此外，与传统抗惊厥药的相互作用不太常见，因此，与这些药物联合治疗显示出耐受性改善。新的抗癫痫药物的可用性使我们能够为每位患者制定个性化的抗惊厥策略。
New antiepileptic drugs have been developed and released for the treatment of chronic focal and secondarily generalized epileptic seizures. The anticonvulsant efficacy of these drugs (vigabatrin, lamotrigine, gabapentin, felbamate, tiagabine, topiramate and oxcarbazepine) does not seem to be superior to that of traditional anticonvulsants. The main advantage of these newly developed drugs is a different spectrum of possible adverse events (i.e. these drugs usually do not induce sedation). Moreover interactions with traditional anticonvulsants are less common, therefore, comedication with these drugs shows an improved tolerability. The availability of new antiepileptic drugs enables us to establish an individually tailored anticonvulsant strategy for each patient.